What is BrainPOP?
The Brain Perioperative Program (BrainPOP) is The Brain Cancer Centre’s core clinical trial and precision medicine platform, designed to accelerate the development of new treatments for brain cancer.
BrainPOP answers the question most brain cancer trials can’t: does the treatment reach the tumour, and what effect does it have.
An integrated platform connecting clinical trials, precision medicine and real-world data across leading institutions.
Why BrainPOP is different
Direct access to tumour tissue before and after treatment
BrainPOP measures whether a treatment reaches the tumour and what biological effect it has.
Integrated platform: clinical trials, tumour profiling and real-world data
Every project generates data that feeds back into the system, allowing insights to be shared and each trial to improve on the last.
Uniquely integrated clinical and research environment
BrainPOP operates within the Parkville precinct, where neurosurgery, oncology and research laboratories sit within metres of each other, enabling rapid biospecimen handling, direct clinical-research collaboration, and faster trial execution.
Proven platform, open for collaboration
BrainPOP has completed early-phase trials, published findings in leading journals including Nature Medicine, leveraged $16.5M in external funding and is actively seeking industry partners for sponsored trials and co-funded research.
Latest News
World first clinical trial brings new hope for brain cancer patients
Victorian researchers have made a global breakthrough, uncovering unprecedented insights into how a new drug can slow the growth of low-grade gliomas (LGG) — a type of brain cancer that mostly affects young adults.
The BrainPOP program is led by The Brain Cancer Centre and delivered in collaboration with The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, University of Melbourne, The Royal Children’s Hospital, Murdoch Children’s Research Institute and WEHI, supported by investment from the Victorian Government.
